{
    "organizations": [],
    "uuid": "3674adc146f0529aa865e2a9c5ce0b2789addbf3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-g1-therapeutics-announces-positive/brief-g1-therapeutics-announces-positive-trilaciclib-phase-2a-topline-data-showing-robust-myelopreservation-benefits-in-patients-with-small-cell-lung-cancer-idUSFWN1QN05G",
    "ord_in_thread": 0,
    "title": "BRIEF-G1 Therapeutics Announces Positive Trilaciclib Phase 2A Topline Data Showing Robust Myelopreservation Benefits In Patients With Small Cell Lung Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 5 (Reuters) - G1 Therapeutics Inc:\n* G1 THERAPEUTICS ANNOUNCES POSITIVE TRILACICLIB PHASE 2A TOPLINE DATA SHOWING ROBUST MYELOPRESERVATION BENEFITS IN PATIENTS WITH SMALL CELL LUNG CANCER\n* G1 THERAPEUTICS - CURRENTLY CONDUCTING TWO ADDITIONAL CLINICAL TRIALS OF TRILACICLIB WITH PRELIMINARY DATA FROM BOTH EXPECTED IN Q4 2018\n* G1 THERAPEUTICS - TRILACICLIB REDUCED CLINICALLY RELEVANT CONSEQUENCES OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION VERSUS PLACEBO\n* G1 THERAPEUTICS INC - STATISTICALLY SIGNIFICANT RESULTS FROM PHASE 2A TRIAL EVALUATING TRILACICLIB Source text for Eikon: Further company coverage:\n ",
    "published": "2018-03-05T19:31:00.000+02:00",
    "crawled": "2018-03-06T22:05:27.006+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "g1",
        "therapeutic",
        "inc",
        "g1",
        "therapeutic",
        "announces",
        "positive",
        "trilaciclib",
        "phase",
        "2a",
        "topline",
        "data",
        "showing",
        "robust",
        "myelopreservation",
        "benefit",
        "patient",
        "small",
        "cell",
        "lung",
        "cancer",
        "g1",
        "therapeutic",
        "currently",
        "conducting",
        "two",
        "additional",
        "clinical",
        "trial",
        "trilaciclib",
        "preliminary",
        "data",
        "expected",
        "q4",
        "g1",
        "therapeutic",
        "trilaciclib",
        "reduced",
        "clinically",
        "relevant",
        "consequence",
        "myelosuppression",
        "versus",
        "placebo",
        "g1",
        "therapeutic",
        "inc",
        "statistically",
        "significant",
        "result",
        "phase",
        "2a",
        "trial",
        "evaluating",
        "trilaciclib",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}